63,766 Shares in Qiagen N.V. (NYSE:QGEN) Purchased by ASR Vermogensbeheer N.V.

Key Points

• ASR Vermogensbeheer N.V. acquired 63,766 shares of Qiagen N.V. valued at approximately $2.5 million in the first quarter, indicating significant institutional interest in the stock.
• Several analysts have revised their price targets for Qiagen, with Barclays setting a new price objective of $55 and Bank of America increasing its target from $50 to $53, reflecting positive sentiment in the market.
• Qiagen reported a quarterly earnings per share of $0.60, meeting analysts' expectations, alongside a 7.7% increase in revenue compared to the previous year.

ASR Vermogensbeheer N.V. bought a new stake in shares of Qiagen N.V. (NYSE:QGEN - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 63,766 shares of the company's stock, valued at approximately $2,526,000.

A number of other large investors also recently modified their holdings of QGEN. Baader Bank Aktiengesellschaft boosted its stake in Qiagen by 8.1% during the first quarter. Baader Bank Aktiengesellschaft now owns 53,223 shares of the company's stock valued at $2,131,000 after buying an additional 4,009 shares during the period. Federated Hermes Inc. purchased a new stake in shares of Qiagen in the 1st quarter valued at about $150,000. Cetera Investment Advisers boosted its position in shares of Qiagen by 23.2% during the 1st quarter. Cetera Investment Advisers now owns 13,917 shares of the company's stock valued at $551,000 after acquiring an additional 2,620 shares during the last quarter. Avantax Advisory Services Inc. grew its holdings in shares of Qiagen by 30.2% during the first quarter. Avantax Advisory Services Inc. now owns 9,869 shares of the company's stock worth $396,000 after purchasing an additional 2,290 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd bought a new position in shares of Qiagen in the first quarter worth approximately $94,000. 70.00% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Cowen reissued a "hold" rating on shares of Qiagen in a research note on Thursday. Wall Street Zen raised Qiagen from a "buy" rating to a "strong-buy" rating in a research note on Sunday, August 3rd. Barclays started coverage on Qiagen in a report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price objective for the company. UBS Group raised their price objective on Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a report on Thursday. Finally, Bank of America boosted their target price on Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. Eight analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $49.69.

Qiagen Price Performance

QGEN opened at $48.32 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.37 and a quick ratio of 2.83. The stock's 50 day simple moving average is $47.96 and its 200 day simple moving average is $43.55. The firm has a market cap of $10.74 billion, a price-to-earnings ratio of 28.55, a PEG ratio of 2.41 and a beta of 0.64. Qiagen N.V. has a 1 year low of $37.63 and a 1 year high of $51.88.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting the consensus estimate of $0.60. The business had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The firm's revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.55 EPS. As a group, analysts predict that Qiagen N.V. will post 2.26 earnings per share for the current year.

Qiagen Dividend Announcement

The firm also recently announced a dividend, which was paid on Thursday, July 10th. Investors of record on Thursday, July 3rd were paid a $0.25 dividend. The ex-dividend date of this dividend was Wednesday, July 2nd. This represents a dividend yield of 52.0%. Qiagen's dividend payout ratio (DPR) is presently 14.79%.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NYSE:QGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.